Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TOS 358

Next Previous
Search
Drug Profile

TOS 358

Alternative Names: TOS-358

Latest Information Update: 01 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Totus Medicines
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Research Cancer; CNS cancer; Colorectal cancer; Haematological malignancies; Lung cancer

Most Recent Events

  • 13 Sep 2024 Efficacy, safety and pharmacokinetics data from a phase-I clinical trials in Solid tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
  • 10 Apr 2023 US FDA approves IND application for TOS 358 in Solid tumours, before February 2023
  • 15 Feb 2023 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Recurrent, Second-line therapy or greater) in Spain (PO) (NCT05683418)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top